Mvasi is approved to treat patients with certain colorectal, lung, brain, kidney and cervical cancers in combination with other therapies.
Mvasi is the first biosimilar approved by the FDA to treat cancer and represents one of four oncology bisomilars Amgen and Allergan are co-developing.
More articles on supply chain:
Teva to sell contraceptive device business for $1.1B, divest remaining women’s health assets
FDA reapproves leukemia drug 7 years after pulled from market
Supply chain inefficiencies leave $23B in potential savings on the table for hospitals
Register to Attend Webinar
Presenters:
James Germano, MD, Joint Reconstruction Specialist|Tim Tzimas, Innovative Sterilization Technologies
Next Up in Supply Chain
-
Ville Platte, La.-based Mercy Regional Medical Center has signed a prime vendor agreement with Medline for medical-surgical products and distribution…
-
Three group purchasing organizations served as the primary GPOs for more than 80% of U.S. hospitals in 2024, according to…
-
The federal government has invested $15.97 million in a project designed to establish a fully domestic pharmaceutical supply chain in…
Join the 500,000+ healthcare executives who start their day with Becker's
Becker's Hospital Review Newsletter is sent Monday–Sunday.
